Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | UNG | P13051 | 1/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.38 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5621958 | 0.90 | SMN1; SMN2 (0.40) | KMT2AKDM4EPKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5620706 | 0.84 | RAF1 (0.38) | KDM4EALDH1A1TDP1 | |
| SCHEMBL5622762 | 0.82 | NPC1 (0.35) | KDM4EPKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5652991 | 0.81 | ITGB3 (0.34) | KDM4EPKMSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL5622226 | 0.81 | NOS1 (0.33) | KMT2AKDM4EPKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5621751 | 0.81 | KDM4E (0.33) | KDM4EPKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5621956 | 0.81 | ROCK2 (0.36) | ROCK2ROCK1KDM4EPKMSMN1; SMN2 | |
| SCHEMBL5622643 | 0.80 | KDM4E (0.33) | KDM4EPKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5620841 | 0.80 | RXFP1 (0.40) | KMT2AMRGPRX4MEP1BACMSDPKM | |
| SCHEMBL5652587 | 0.78 | ABCB1 (0.38) | KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | claimed |
| US-20050038016-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | claimed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050038016-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | FABP4 2490/4885KMT2A 2952/4885ROCK2 2245/4885 |
| US-20050038016-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | FABP4 2490/4885KMT2A 2952/4885ROCK2 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.